12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Albiglutide: Phase III data

The double-blind, international Phase III Harmony 2 trial in 296 previously untreated Type II diabetics showed that once-weekly subcutaneous 30 and 50 mg doses of albiglutide each met the primary endpoint of reducing HbA1c from baseline to week 52 vs. placebo. Specifically, placebo-adjusted reductions in HbA1c were 0.84% for low-dose albiglutide and 1.04% for high-dose albiglutide (p<0.0001 for both). On secondary endpoints, low-dose albiglutide reduced FPG by 34 mg/dL and...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >